Abstract: Disclosed is a novel piperidinedione compound of Formula 1 or a pharmaceutically acceptable salt thereof. Uses of the novel piperidinedione compound of Formula 1 or a pharmaceutically acceptable salt thereof as an anti-tumor agent or an immunomodulatory for treatment of CRBN protein-mediated diseases are disclosed. Also the compound or salt thereof can be used an E3 ligase binder in a PROTAC compound comprising a protein of interest ligand, a linker and an E3 ligase binder.

Abstract: The present invention relates to a method for protecting a kidney, which comprises administering an extracellular polysaccharide produced by Ceriporia lacerata; a mycelial culture medium of Ceriporia lacerata containing the extracellular polysaccharide; dried powders of the mycelial culture medium; or an extract of the mycelial culture medium, in an effective amount, to a subject in need of protecting a kidney. The method is effective in protecting a kidney from renal toxicity caused by an anti-cancer agent.

Abstract: The present invention relates to a method for protecting a kidney, which comprises administering an extracellular polysaccharide produced by Ceriporia lacerata; a mycelial culture medium of Ceriporia lacerata containing the extracellular polysaccharide; dried powders of the mycelial culture medium; or an extract of the mycelial culture medium, in an effective amount, to a subject in need of protecting a kidney. The method is effective in protecting a kidney from renal toxicity caused by an anti-cancer agent.

Abstract: The present invention provides a method for separating and preparing a therapeutic agent for chronic myelogenous leukimeia capable of effectively inhibiting growth of T315I, which is known as a mutation of a BCR-ABL fusion gene that causes chronic myelogenous leukemia, comprising the steps of: 1) preliminary extracting by adding ethyl acetate to finely chopped bark of Liriodendron tulipifera L., adding butanol to an extracted fluid for layer-separating an ethyl acetate layer and a butanol layer, removing the butanol layer, and decompression-condensing the remainder to obtain a crude extract; and 2) adding a C1-C3 lower alcohol aqueous solution and n-hexane to the obtained crude extract, removing lipids and water insoluble material dissolved in the n-hexane layer, and obtaining and separating a lower alcohol aqueous solution layer to separate and refine highly pure epi-tulipinolide and costunolide.

Abstract: The present invention relates to a pharmaceutical composition containing, as an active ingredient, a Liriodendron tulipifera L. bark extract for treating chronic myelogneous leukemia. More specifically, the present invention relates to the pharmaceutical composition, containing, as the active ingredient, the Liriodendron tulipifera L. bark extract useful in selectively inhibiting mutant enzyme T315I from a mutation of a BCR-ABL fusion gene that causes chronic myelogenous leukemia, and to a use of epi-Tulipinolide which is an active ingredient of the composition.

Abstract: The present invention relates to a sesquiterpene lactone-based pharmaceutical composition for treating gastrointestinal diseases. More particularly, the present invention relates to a pharmaceutical composition, containing as an active ingredient a sesquiterpene lactone-based derivative derived from parthenolide, for preventing or treating gastritis or gastric ulcers.

Abstract: The present invention relates to a sesquiterpene lactone-based pharmaceutical composition for treating gastrointestinal diseases. More particularly, the present invention relates to a pharmaceutical composition, containing as an active ingredient a sesquiterpene lactone-based derivative derived from parthenolide, for preventing or treating gastritis or gastric ulcers.

Abstract: The present invention relates to a sesquiterpene lactone-based pharmaceutical composition for treating gastrointestinal diseases. More particularly, the present invention relates to a pharmaceutical composition, containing as an active ingredient, a sesquiterpene lactone-based derivative derived from parthenolide, for preventing or treating gastritis or gastric ulcers.